Chimeric Therapeutics Ltd (ASX: CHM) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Chimeric Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Chimeric Therapeutics Ltd (ASX: CHM)
Latest News
Healthcare Shares
Guess which ASX micro-cap stock is rocketing 80% on FDA clearance
Healthcare Shares
Do ASX biotech shares offer 'good buying' after the sell-off? Experts weigh in
Share Gainers
The Chimeric (ASX:CHM) share price jumps 6% on patent success
Healthcare Shares
The Chimeric (ASX:CHM) share price drops despite cancer trial news
Share Market News
Chimeric (ASX:CHM) share price finishes flat on quarterly update
Share Market News
Chimeric (ASX:CHM) share price edges lower despite positive update
Share Market News
Chimeric (ASX:CHM) share price falls despite positive update
Share Market News
Chimeric Therapeutics (ASX:CHM) share price jumps 88% following its IPO
CHM ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Chimeric Therapeutics Ltd
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.
CHM Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
08 Nov 2024 | $0.01 | $0.00 | 0.00% | 3,639,441 | $0.01 | $0.01 | $0.01 |
07 Nov 2024 | $0.01 | $0.00 | 0.00% | 1,300,590 | $0.01 | $0.01 | $0.01 |
06 Nov 2024 | $0.01 | $0.00 | 0.00% | 235,909 | $0.01 | $0.01 | $0.01 |
05 Nov 2024 | $0.01 | $0.00 | 0.00% | 13,870,948 | $0.01 | $0.01 | $0.01 |
04 Nov 2024 | $0.01 | $0.00 | 0.00% | 4,610,848 | $0.01 | $0.01 | $0.01 |
01 Nov 2024 | $0.01 | $0.00 | 0.00% | 1,077,366 | $0.01 | $0.01 | $0.01 |
31 Oct 2024 | $0.01 | $0.00 | 0.00% | 2,126,078 | $0.01 | $0.01 | $0.01 |
30 Oct 2024 | $0.01 | $0.00 | 0.00% | 3,061,708 | $0.01 | $0.01 | $0.01 |
29 Oct 2024 | $0.01 | $0.00 | 0.00% | 4,145,093 | $0.01 | $0.01 | $0.01 |
28 Oct 2024 | $0.01 | $0.00 | 0.00% | 5,993,852 | $0.01 | $0.01 | $0.01 |
25 Oct 2024 | $0.01 | $0.00 | 0.00% | 7,828,146 | $0.01 | $0.01 | $0.01 |
24 Oct 2024 | $0.01 | $0.00 | 0.00% | 9,609,391 | $0.01 | $0.01 | $0.01 |
23 Oct 2024 | $0.01 | $0.00 | 0.00% | 3,701,576 | $0.01 | $0.01 | $0.01 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
14 Dec 2023 | Jennifer Chow | Issued | 8,643,603 | $302,526 |
Issue of securities.
|
14 Dec 2023 | Jennifer Chow | Issued | 4,062,997 | $109,700 |
Issue of securities. 4,062,997 Rights
|
14 Dec 2023 | Jennifer Chow | Issued | 15,139,467 | $408,765 |
Issue of options. As per announcement on 15-12-2023
|
14 Dec 2023 | Eric Sullivan | Issued | 2,750,000 | $74,250 |
Issue of options.
|
07 Dec 2023 | Phillip Hains | Issued | 3,571,429 | $100,000 |
Rights issue.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Phillip Hains | Chief Financial OfficerJoint Company SecretaryNon Executive Director | Jul 2023 |
Mr Hains has over 30 years of experience in corporate secretarial, accounting and general management through his firm The CFO Solution, a boutique professional services firm for listed companies. Mr Hains is currently the Company Secretary of several ASX listed companies including Imugene Ltd (ASX:IMU), Immuron Ltd (ASX:IMC), SelfWealth Limited (ASX:SWF), Total Brain Limited (ASX:TTB) and SUDA Pharmaceuticals Ltd (ASX:SUD).
|
Mr Paul Alex Hopper | FounderExecutive ChairmanExecutive Director | Feb 2020 |
Mr Hopper has over 20 years' experience in the management and funding of biotechnology and healthcare public companies as chairman, chief executive officer and director in Australia and the United States. Mr Hopper's sector experience has covered a number of therapeutic areas with a particular emphasis on immunotherapy. He also has extensive capital markets experience in equity and debt raisings in Australia, Asia, Europe, and the United States.
|
Dr Lesley Russell | Non-Executive Director | Aug 2020 |
Dr Russell has over 25 years' experience and leadership in the international pharmaceutical field as a chief medical officer. She has undertaken clinical development in a number of therapeutic areas including haematology/oncology has had multiple new drug approvals with both FDA and European Medicines Agency (EMA). Dr Russell has extensive experience as a director of NASDAQ listed pharmaceutical companies. She is a member of the Royal College of Physicians UK. She is member of the risk committee.
|
Mr Eric Sullivan | Non-Executive Director | Aug 2023 |
Mr Sullivan is a senior finance and operations leader in private-to-public biotechnology company building, strategy, fundraising and financial planning. He brings with him an background in the biotechnology sector, having served in senior finance and operations leadership roles across a number of high-growth public biotech companies, including bluebird bio, Merrimack Pharmaceuticals and TCR2 Therapeutics. Additionally, his experience with blue-chip private companies, such as Oncorus, Gemini Therapeutics, and Triplet Therapeutics.
|
Mr Nathan Jong | Joint Company Secretary |
-
|
|
Eliot Bourk | Chief Business Officer |
-
|
|
Jason Litten | Chief Medical Officer |
-
|
|
Nathan Jong | Joint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Paul Hopper | 94,994,574 | 17.94% |
Lind Global Fund II LP | 17,624,724 | 3.33% |
Christine Brown | 11,696,565 | 2.21% |
Michael E Barish | 11,522,634 | 2.18% |
Zerrin Investments Pty Ltd | 9,600,001 | 1.81% |
Jennifer Chow | 9,450,924 | 1.79% |
Hsbc Custody Nominees (Australia) Limited | 9,437,237 | 1.78% |
Citicorp Nominees Pty Limited | 8,540,926 | 1.61% |
Shared Office Services Pty Ltd <Philanne S/F A/C> | 6,521,739 | 1.23% |
Valentino Trading Pty Ltd | 5,500,000 | 1.04% |
Kamala Holdings Pty Ltd <The Kamala 1994 S/F A/C> | 5,447,142 | 1.03% |
Australian Direct Investments Pty Limited <Super Fund A/C> | 5,060,000 | 0.96% |
Liberty National Pty Ltd <Liberty National Family A/C> | 5,000,000 | 0.94% |
Ubs Nominees Pty Ltd | 4,945,588 | 0.93% |
Mr Lutz Steffens & Mrs Katy Steffens | 4,303,341 | 0.81% |
Solium Nominees (Australia) Pty Ltd | 4,087,272 | 0.77% |
Mr Tim Bensley & Ms Jenny Jiaer Zhang | 3,961,562 | 0.75% |
Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> | 3,655,335 | 0.69% |
Alpha Beta Superannuation Services Pty Ltd <The Alpha Beta Sf A/C> | 3,357,142 | 0.63% |
Brispot Nominees Pty Ltd <House Head Nominee A/C> | 3,243,205 | 0.61% |